Implementing Control-IQ technology after a virtual educational camp in children and adolescents with type 1 diabetes: Does time in range plateau over 1 year?

IR serves on the advisory board for Sanofi Aventis and Movi and has spoken for Aboca, Abbott, Sanofi Aventis and Eli Lilly. VC serves on the advisory board for Insulet and Eli Lilly, and his institution has received research support from AstraZeneca, Eli Lilly and Dompè. MM serves on the advisory board for Medtronic and Movi, has received support for attending meetings from Movi and has spoken for Abbott and Roche. RS has spoken for Abbott and Lilly, has received support for attending meetings from Medtronic and Movi and has served on advisory boards for Abbott and Sanofi. ST has spoken for Eli Lilly, Abbott and Sanofi Aventis and serves on the advisory board for Movi. AES has spoken for Sanofi and Abbott, has received support for attending meetings from Movi and has served on the advisory board for Medtronic and Movi. RB has served on the advisory board for NovoNordisk, Eli Lilly, Sanofi Aventis, Abbott, Medtronic, Movi, Roche and Ypsomed and has received support for attending a meeting from Movi and has spoken for Eli Lilly, Abbott and Sanofi Aventis. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15343. Data are available upon reasonable request from the corresponding author. Figure S1. Sustained improvement in TIR 12 months after upgrading from Basal-IQ to Control-IQ technology and after attending a virtual educational camp in children (n = 21) and adolescents (n = 22) with type 1 diabetes, evaluated according their age group. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.